Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Global Orphan Drugs Market Size, Share, Trends, and Forecast 2026-2034 | Market to Reach USD 589.2 Billion as Genomics, Precision Medicine, and Regulatory Incentives Drive Growth

globenewswire.com
AMGN Amgen Inc. is identified as a leading company in the orphan drugs market, an industry expected to experience significant growth. The article does not offer specific sentiment for Amgen but includes it among major players. AZN AstraZeneca is named as a key company operating in the expanding global orphan drugs market. The article mentions strategic partnerships and investment priorities relevant to the sector but provides no specific sentiment for AstraZeneca. GNE Genentech USA, Inc. is listed as a key player in the orphan drugs market, which is expected to grow significantly. The article does not provide specific sentiment for the company but notes its presence in a growing sector. GSK GSK plc is identified as a leading company in the orphan drugs market, which is projected for strong expansion. The article does not offer specific sentiment for GSK but includes it among major industry participants. JNJ Johnson & Johnson is named as a key company operating within the growing global orphan drugs market. The article highlights industry growth drivers but provides no specific sentiment for Johnson & Johnson. MRK Merck & Co., Inc. is listed as a key player in the orphan drugs market, which is expected to grow substantially. The article does not provide specific sentiment for Merck but includes it among major companies in the sector. NVS Novartis Pharmaceuticals Corporation is identified as a leading company in the orphan drugs market, which is projected for strong expansion. The article does not offer specific sentiment for Novartis but names it as a key player. PFE Pfizer Inc. is named as a key company operating in the expanding global orphan drugs market. The article highlights industry growth drivers like genomics and precision medicine but provides no specific sentiment for Pfizer. SNY Sanofi S.A. is listed as a key player in the orphan drugs market, which is expected to grow substantially. The article does not provide specific sentiment for Sanofi but includes it among major companies in the sector. BMY Bristol Myers Squibb is mentioned indirectly through its drug 'Revlimid' which is a top-selling orphan drug. The article does not provide specific sentiment for the company itself but highlights the success of its product. REGN Regeneron Pharmaceuticals, Inc. is mentioned indirectly through its drug 'Opdivo' which is a top-selling orphan drug. The article does not provide specific sentiment for the company itself but highlights the success of its product. BIIB Biogen Inc. is mentioned indirectly through its drug 'Avonex' which is a top-selling orphan drug. The article does not provide specific sentiment for the company itself but highlights the success of its product. GILD Gilead Sciences, Inc. is mentioned indirectly through its drug 'Soliris' which is a top-selling orphan drug. The article does not provide specific sentiment for the company itself but highlights the success of its product. ABBV AbbVie Inc. is mentioned indirectly through its drug 'Imbruvica' which is a top-selling orphan drug. The article does not provide specific sentiment for the company itself but highlights the success of its product. EXEL Exelixis, Inc. is mentioned indirectly through its drug 'Copaxone' which is a top-selling orphan drug. The article does not provide specific sentiment for the company itself but highlights the success of its product. CRSP CRISPR Therapeutics AG is mentioned as a company involved in gene therapy, a key area in the orphan drugs market. The article does not provide specific sentiment but places it in a growth sector. NTLA Intellia Therapeutics, Inc. is mentioned as a company involved in gene therapy, a key area in the orphan drugs market. The article does not provide specific sentiment but places it in a growth sector. EDIT Editas Medicine, Inc. is mentioned as a company involved in gene therapy, a key area in the orphan drugs market. The article does not provide specific sentiment but places it in a growth sector. INCY Incyte Corporation is mentioned indirectly through its drug 'Ruxolitinib' (Jakafi) which is used for myelofibrosis, a rare disease. The article does not provide specific sentiment for the company but highlights the success of its product. VRTX Vertex Pharmaceuticals Incorporated is mentioned as a company involved in precision medicine and rare disease treatments. The article does not provide specific sentiment but places it in a growth sector.

Global Orphan Drugs Market Size, Share, Trends, and Forecast 2026-2034 | Market to Reach USD 589.2 Billion as Genomics, Precision Medicine, and Regulatory Incentives Drive Growth Dublin, Oct. 06, 2026 (GLOBE NEWSWIRE) -- "Orphan Drugs Market Size, Share, Trends and Forecast by Drug Type, Disease Type, Phase, Top Selling Drugs, Distribution Channel, and Region, 2026-2034" has been added to ResearchAndMarkets.com's offering.

The global orphan drugs market was valued at USD 261.0 Billion in 2025 and is projected to reach USD 589.2 Billion by 2034, expanding at a CAGR of 9.47% from 2026-2034. North America led the market in 2025 with a 35.5% share, supported by favorable regulatory policies, advanced healthcare infrastructure, strong research capabilities, and continued investment in rare disease treatments.

Global orphan drugs market growth is being driven by greater awareness of rare diseases, advances in genomics and precision medicine, improved diagnostic technologies, and government incentives for pharmaceutical innovation. Regulatory benefits such as market exclusivity, tax credits, fee waivers, research grants, and accelerated approval pathways reduce development risks and encourage investment in treatments for small patient populations with significant unmet medical needs.

Approximately 300 million people worldwide were estimated to be living with rare diseases in 2024. Patient registries, epidemiological research, advocacy organizations, and public awareness campaigns are improving disease recognition and supporting earlier diagnosis. These developments are expanding the identifiable patient population and increasing demand for targeted orphan therapies.

Technology and Regulatory Trends

Genomic sequencing, bioinformatics, companion diagnostics, and personalized medicine are reshaping rare disease diagnosis and drug development. These technologies enable pharmaceutical and biotechnology companies to identify genetic markers, improve patient selection, and develop treatments aligned with specific disease mechanisms. Innovation is particularly strong in biologics, gene therapies, cell-based medicines, monoclonal antibodies, and ribonucleic acid (RNA)-based treatments. The companion diagnostics market is forecast to reach USD 22.3 Billion by 2033, further supporting targeted drug development.

Government funding also contributes to market expansion. In India, plans were announced to establish a National Fund for Rare Diseases (NFRD), with proposed funding of ?974 crore for FYs 2024-25 and 2025-26, subject to Ministry of Health and Family Welfare clearance. Comparable or higher funding has been proposed for 2026-27 and 2027-28.

United States Orphan Drugs Market

The United States accounts for 93.00% of the North American market. Growth is supported by the Orphan Drug Act, expedited regulatory reviews, market exclusivity, favorable reimbursement practices, private and public research funding, and an estimated rare disease population exceeding 30 million people.

In 2025, the US Food and Drug Administration awarded orphan drug status to rilzabrutinib, an experimental oral, reversible Bruton's tyrosine kinase (BTK) inhibitor, for warm autoimmune hemolytic anemia (wAIHA) and IgG4-related disease (IgG4-RD). Pharmaceutical investment also remains active, with 25 private equity deals announced in the US pharmaceutical industry during Q3 2024, representing a combined value of USD 2.3 Billion.

Orphan Drugs Market Segmentation

Biological therapies represented 65.8% of the market in 2025. Their leadership reflects the growing use of monoclonal antibodies, recombinant proteins, gene therapies, and cell-based treatments for complex genetic, immunological, metabolic, and oncological conditions. Strong development pipelines and regulatory mechanisms such as fast-track approval and orphan designation continue to support this segment.

Oncology accounted for 36.6% of the market, making it the leading disease category. Demand is driven by the need for targeted treatments for rare cancers, including specific leukemias, lymphomas, and sarcomas. Advances in immunotherapy, biomarker-led research, and molecular biology are accelerating the development of therapies for uncommon cancer subtypes.

Keytruda held 15.7% of the market among top-selling drugs. The PD-1 inhibitor is used for several oncology indications, including rare cancers such as Merkel cell carcinoma and primary mediastinal large B-cell lymphoma. Other prominent products include Revlimid, Rituxan, Copaxone, Opdivo, Imbruvica, Avonex, Sensipar, and Soliris.

Hospital pharmacies accounted for 48.2% of orphan drug distribution. Their leading position is supported by the specialized administration, monitoring, inventory management, and reimbursement requirements associated with many high-cost rare disease therapies.

Regional Orphan Drugs Market Outlook

Competitive Landscape

Competition in the global orphan drugs market is intensifying as pharmaceutical and biotechnology companies pursue strategic partnerships, mergers and acquisitions (M&A), licensing agreements, and research collaborations. Investment priorities include gene therapy, immunotherapy, precision medicine, AI-powered drug discovery, and rare oncology. Partnerships between specialty biotechnology companies and large pharmaceutical groups are helping combine early-stage innovation with clinical development, regulatory, manufacturing, and commercialization capabilities.

Leading companies operating in the orphan drugs market include Alexion Pharmaceuticals Inc., Amgen Inc., AstraZeneca, Bayer AG, Daiichi Sankyo Company Limited, Genentech USA, Inc (F. Hoffmann-La Roche AG), GSK plc, Johnson & Johnson, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc., Sanofi S.A., and Takeda Pharmaceuticals U.S.A., Inc.

With sustained regulatory support, improved rare disease diagnosis, growing therapeutic pipelines, and rapid progress in precision medicine, the global orphan drugs market is positioned for strong expansion through 2034.

Key Attributes

Key Topics Covered

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study

2.2 Stakeholders

2.3 Data Sources

2.3.1 Primary Sources

2.3.2 Secondary Sources

2.4 Market Estimation

2.4.1 Bottom-Up Approach

2.4.2 Top-Down Approach

2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

4.1 Overview

4.2 Key Industry Trends

5 Global Orphan Drugs Market

5.1 Market Overview

5.2 Market Performance

5.3 Impact of COVID-19

5.4 Market Forecast

6 Market Breakup by Drug Type

6.1 Biological

6.1.1 Market Trends

6.1.2 Market Forecast

6.2 Non-Biological

6.2.1 Market Trends

6.2.2 Market Forecast

7 Market Breakup by Disease Type

7.1 Oncology

7.1.1 Market Trends

7.1.2 Market Forecast

7.2 Hematology

7.2.1 Market Trends

7.2.2 Market Forecast

7.3 Neurology

7.3.1 Market Trends

7.3.2 Market Forecast

7.4 Cardiovascular

7.4.1 Market Trends

7.4.2 Market Forecast

7.5 Others

7.5.1 Market Trends

7.5.2 Market Forecast

8 Market Breakup by Phase

8.1 Phase I

8.1.1 Market Trends

8.1.2 Market Forecast

8.2 Phase II

8.2.1 Market Trends

8.2.2 Market Forecast

8.3 Phase III

8.3.1 Market Trends

8.3.2 Market Forecast

8.4 Phase IV

8.4.1 Market Trends

8.4.2 Market Forecast

9 Market Breakup by Top Selling Drugs

9.1 Revlimid

9.1.1 Market Trends

9.1.2 Market Forecast

9.2 Rituxan

9.2.1 Market Trends

9.2.2 Market Forecast

9.3 Copaxone

9.3.1 Market Trends

9.3.2 Market Forecast

9.4 Opdivo

9.4.1 Market Trends

9.4.2 Market Forecast

9.5 Keytruda

9.5.1 Market Trends

9.5.2 Market Forecast

9.6 Imbruvica

9.6.1 Market Trends

9.6.2 Market Forecast

9.7 Avonex

9.7.1 Market Trends

9.7.2 Market Forecast

9.8 Sensipar

9.8.1 Market Trends

9.8.2 Market Forecast

9.9 Soliris

9.9.1 Market Trends

9.9.2 Market Forecast

9.10 Others

9.10.1 Market Trends

9.10.2 Market Forecast

10 Market Breakup by Distribution Channel

10.1 Hospital Pharmacies

10.1.1 Market Trends

10.1.2 Market Forecast

10.2 Retail Pharmacies

10.2.1 Market Trends

10.2.2 Market Forecast

10.3 Online Stores

10.3.1 Market Trends

10.3.2 Market Forecast

10.4 Others

10.4.1 Market Trends

10.4.2 Market Forecast

11 Market Breakup by Region

11.1 North America

11.1.1 United States

11.1.1.1 Market Trends

11.1.1.2 Market Forecast

11.1.2 Canada

11.1.2.1 Market Trends

11.1.2.2 Market Forecast

11.2 Asia Pacific

11.2.1 China

11.2.1.1 Market Trends

11.2.1.2 Market Forecast

11.2.2 Japan

11.2.2.1 Market Trends

11.2.2.2 Market Forecast

11.2.3 India

11.2.3.1 Market Trends

11.2.3.2 Market Forecast

11.2.4 South Korea

11.2.4.1 Market Trends

11.2.4.2 Market Forecast

11.2.5 Australia

11.2.5.1 Market Trends

11.2.5.2 Market Forecast

11.2.6 Indonesia

11.2.6.1 Market Trends

11.2.6.2 Market Forecast

11.2.7 Others

11.2.7.1 Market Trends

11.2.7.2 Market Forecast

11.3 Europe

11.3.1 Germany

11.3.1.1 Market Trends

11.3.1.2 Market Forecast

11.3.2 France

11.3.2.1 Market Trends

11.3.2.2 Market Forecast

11.3.3 United Kingdom

11.3.3.1 Market Trends

11.3.3.2 Market Forecast

11.3.4 Italy

11.3.4.1 Market Trends

11.3.4.2 Market Forecast

11.3.5 Spain

11.3.5.1 Market Trends

11.3.5.2 Market Forecast

11.3.6 Russia

11.3.6.1 Market Trends

11.3.6.2 Market Forecast

11.3.7 Others

11.3.7.1 Market Trends

11.3.7.2 Market Forecast

11.4 Latin America

11.4.1 Brazil

11.4.1.1 Market Trends

11.4.1.2 Market Forecast

11.4.2 Mexico

11.4.2.1 Market Trends

11.4.2.2 Market Forecast

11.4.3 Others

11.4.3.1 Market Trends

11.4.3.2 Market Forecast

11.5 Middle East and Africa

11.5.1 Market Trends

11.5.2 Market Breakup by Country

11.5.3 Market Forecast

12 SWOT Analysis

12.1 Overview

12.2 Strengths

12.3 Weaknesses

12.4 Opportunities

12.5 Threats

13 Value Chain Analysis

14 Porters Five Forces Analysis

14.1 Overview

14.2 Bargaining Power of Buyers

14.3 Bargaining Power of Suppliers

14.4 Degree of Competition

14.5 Threat of New Entrants

14.6 Threat of Substitutes

15 Price Analysis

16 Competitive Landscape

16.1 Market Structure

16.2 Key Players

16.3 Profiles of Key Players

16.3.1 Alexion Pharmaceuticals Inc.

16.3.1.1 Company Overview

16.3.1.2 Product Portfolio

16.3.1.3 Financials

16.3.1.4 SWOT Analysis

16.3.2 Amgen Inc.

16.3.2.1 Company Overview

16.3.2.2 Product Portfolio

16.3.2.3 Financials

16.3.2.4 SWOT Analysis

16.3.3 AstraZeneca

16.3.3.1 Company Overview

16.3.3.2 Product Portfolio

16.3.3.3 Financials

16.3.3.4 SWOT Analysis

16.3.4 Bayer AG

16.3.4.1 Company Overview

16.3.4.2 Product Portfolio

16.3.4.3 Financials

16.3.4.4 SWOT Analysis

16.3.5 Daiichi Sankyo Company Limited

16.3.5.1 Company Overview

16.3.5.2 Product Portfolio

16.3.5.3 Financials

16.3.5.4 SWOT Analysis

16.3.6 Genentech USA, Inc (F. Hoffmann-La Roche AG)

16.3.6.1 Company Overview

16.3.6.2 Product Portfolio

16.3.6.3 SWOT Analysis

16.3.7 GSK plc

16.3.7.1 Company Overview

16.3.7.2 Product Portfolio

16.3.7.3 Financials

16.3.7.4 SWOT Analysis

16.3.8 Johnson & Johnson

16.3.8.1 Company Overview

16.3.8.2 Product Portfolio

16.3.8.3 Financials

16.3.8.4 SWOT Analysis

16.3.9 Merck & Co., Inc.

16.3.9.1 Company Overview

16.3.9.2 Product Portfolio

16.3.9.3 Financials

16.3.9.4 SWOT Analysis

16.3.10 Novartis Pharmaceuticals Corporation

16.3.10.1 Company Overview

16.3.10.2 Product Portfolio

16.3.10.3 Financials

16.3.10.4 SWOT Analysis

16.3.11 Pfizer Inc.

16.3.11.1 Company Overview

16.3.11.2 Product Portfolio

16.3.11.3 Financials

16.3.11.4 SWOT Analysis

16.3.12 Sanofi S.A.

16.3.12.1 Company Overview

16.3.12.2 Product Portfolio

16.3.12.3 Financials

16.3.12.4 SWOT Analysis

16.3.13 Takeda Pharmaceuticals U.S.A., Inc

16.3.13.1 Company Overview

16.3.13.2 Product Portfolio

16.3.13.3 Financials

16.3.13.4 SWOT Analysis

List of Figures [110]

List of Tables [9]

For more information about this report visit https://www.researchandmarkets.com/r/u6we77

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.